TRZ Series 30 mg is provisionally associated with tirzepatide, a synthetic dual GIP and GLP-1 receptor agonist. Tirzepatide has been studied for its effects on metabolic signalling pathways involved in glucose regulation, appetite, and digestive physiology.
Research Areas
GIP receptor signalling: Investigation of pathways associated with glucose-dependent insulinotropic polypeptide activity.
GLP-1 receptor signalling: Study of receptor pathways involved in glucose regulation and appetite-related processes.
Glucose metabolism: Research into mechanisms associated with insulin secretion and glucagon regulation.
Appetite-related pathways: Investigation of biological signalling involved in food intake and energy balance.
Gastrointestinal physiology: Research into mechanisms affecting gastric emptying.
Product Specifications
Product label: TRZ Series
Labelled quantity: 30 mg
Proposed compound identity: Tirzepatide — subject to supplier verification
Research category: Metabolic research
Shop at purepeptidestore for premuim quality and service.
